Azelnidipine decreases plasma matrix metalloproteinase-9 levels after endovascular abdominal aortic aneurysm repair

Kurume Medical Journal

Volumn 56, Issue 1-2, 2009, Pages 25-32

  Nakamura, Eiji ^a   Akashi, Hidetoshi ^a   Hiromatsu, Shinichi ^a   Tanaka, Atsuhisa ^a   Onitsuka, Seiji ^a   Aoyagi, Shigeaki ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Abdominal aortic aneurysm; Azelnidipine; Calcium channel antagonist; Endovascular aneurysm repair; Matrix metalloproteinase 9

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZELNIDIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIURETIC AGENT; GELATINASE B; ISOSORBIDE DINITRATE; AZETIDINE 2 CARBOXYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DRUG DERIVATIVE;

ABDOMINAL AORTA ANEURYSM; AGED; ANEURYSM SURGERY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOLEAK; ENDOVASCULAR SURGERY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; REFERENCE VALUE; BLOOD; BLOOD VESSEL TRANSPLANTATION; ENZYMOLOGY; MIDDLE AGED;

AGED; AORTIC ANEURYSM, ABDOMINAL; AZETIDINECARBOXYLIC ACID; BLOOD VESSEL PROSTHESIS IMPLANTATION; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED;

EID: 77950343484     PISSN: 00235679     EISSN: 18812090     Source Type: Journal    
DOI: 10.2739/kurumemedj.56.25     Document Type: Article

References (24)

1. Dorbin PB, and Mrkvicka R. Failure of elastin or collagen as possible critical connective tissue alterations underlying aneurysmal dilatation. Cardiovasc Surg 1994; 2:484-488.
2. Shah PK. Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm. Circulation 1997; 96:2115-2117.
3. William D, and William H. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 1999; 29:122-129.
4. Lorelli DR, Jean-Claude JM, Fox CJ, Clyne J, Cambria RA et al. Response of plasma matrix metalloproteinase-9 to conventional abdominal aortic aneurysm repair or endovascular exclusion: Implications for endoleak. J Vasc Surg 2002; 35:916-922.
5. Nakamura K, Yamagishi S, and Inoue H. Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist. Med Hypotheses 2005; 65:155-157.
6. Yagil Y, and Lustig A. Azelnidipine (CS-905), a novel dihydropyridine calcium channel blocker with gradual onset and prolonged duration of action. Cardiovasc Drug Rev 1995; 13:137-148.
7. Yokokura H, Hiromatsu S, Akashi H, Kato S, and Aoyagi S. Effects of calcium blocker Azelnidipine on experimental abdominal aortic aneurysms. Surg Today 2007; 37:468-473.
8. Fujimoto N, Hosokawa N, Iwata K, Shinya T, Okada Y et al. A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. Clinica Chimica Acta 1994; 231:79-88.
9. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. J Clin Invest 1995; 96:318-326.
10. Hovsepian DM, Ziporin SJ, Sakurai MK, Lee JK, Curci JA et al. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol 2000; 11:1345-1352.
11. Petersen E, Gineitis A, Wågberg F, and Angquist KA. Activity of Matrix Metalloproteinase-2 and -9 in Abdominal Aortic Aneurysms. Relation to Size and Rupture. Eur J Vasc Endovasc Surg 2000; 20:457-461.
12. Sinha S, and Frishman WH. Matrix metalloproteinase and abdominal aortic aneurysms: a potential therapeutic target. J Clin Pharmacol 1998; 38:1077-1088.
13. Moore G, Liao S, Curci JA, Starcher BC, Martin RL et al. Suppression of experimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908). J Vasc Surg 1999; 29:522-532.
14. Curci JA, Petrinec D, Liao S, Golub LM, and Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: Acomparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998; 28:1082-1093.
15. Curci JA, Mao D, Bohner DG, Allen BT, Rubin BG et al. Preoperative treatment with doxycyclines reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 2000; 31:325-342.
16. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC et al. Doxycycline inhibition of aneurysmal degeneration in an easetase-induced rat model of abdominal aortic aneurysm: prevention of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996; 23:336-346.
17. Thompson RW, and Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann NY Acad Sci 1999; 878:159-178.
18. van Laake LW, Vainas T, Dammers R, Kitslaar PJ, Hoeks AP et al. Systemic Dilatation Diathesis with Abdominal Aortic Aneurysms: A Role for Matrix Metalloproteinase-9? Eur J Vasc Endovasc Surg 2005; 29:371-377.
19. Fairman RM, Nolte L, Snyder SA, Chuter TA, Greenberg RK et al. Factors predictive of early or late aneurysm sac size change following endovascular repair. J Vasc Surg 2006; 43:649-656.
20. Naito Y, Shimozawa M, Manabe H, Nakabe N, Katada K et al. Anti-oxidative properties of a new calcium channel blocker azelnidipine. Prog Med 2004; 24:2676-2681. (in Japanese)
21. Matsui T, Yamagishi S, Nakamura K, and Inoue H. Azelnidipine, a new long -acting calcium-channel blocker, inhibits tumor necrosis factor-α-induced monocyte chemoattractant protein-1. Expression in endotherial cells. J Int Med Res 2006; 34:671-675.
22. Kock AE, Kunkel SL, Pearce WH, Shah MR, Parikh D et al. Enhanced Production of the Chemotactic Cytokines Interleukin-8 and Monocyte Chemoattractant Protein-1 in Human Abdominal Aortic Aneurysms. Am J Pathol 1993; 142:1423-1431.
23. McMillan WD, Tamarina NA, Cipollone M, Johnson DA, Parker MA et al. Size matters: The Relationship Between MMP-9 Expression and Aortic Diameter. Circulation 1997; 96: 2228-2232.
24. Hackmann AE, Rubin BG, Sanchez LA, Geraghty PA, Thompson RW et al. A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair. J Vasc Surg 2008; 48:519-526.